Takayasu arteritis that affects the lung arteries: symptoms and long-term outlook
Clinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement
This project will follow people with Takayasu arteritis involving the pulmonary arteries to see what their symptoms, treatments, and long-term outcomes are.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 150 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | China-Japan Friendship Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT07184814 on ClinicalTrials.gov |
What this trial studies
Investigators will prospectively collect and analyze clinical, imaging, and treatment data on patients with Takayasu arteritis and computed tomography–confirmed pulmonary artery involvement admitted to China-Japan Friendship Hospital between January 1, 2016 and December 31, 2026. The work will describe clinical characteristics and current multimodal management patterns and document long-term outcomes. Statistical analyses will explore risk factors for death and factors associated with development of pulmonary hypertension using predefined diagnostic criteria and imaging findings. Patients with other causes of pulmonary artery stenosis or occlusion will be excluded to isolate Takayasu-related involvement.
Who should consider this trial
Good fit: Adults hospitalized at the China-Japan Friendship Hospital between 2016 and 2026 who meet established criteria for Takayasu arteritis and have pulmonary artery involvement confirmed by CT pulmonary angiography or transcatheter pulmonary angiography are ideal candidates.
Not a fit: Patients whose pulmonary artery disease is caused by other conditions (for example, other vasculitides, fibrosing mediastinitis, pulmonary artery sarcoma, sarcoidosis, or chronic thromboembolic pulmonary hypertension) or who do not have CT-confirmed pulmonary artery involvement are unlikely to benefit from this project.
Why it matters
Potential benefit: If successful, the project could help clinicians spot high-risk patients earlier and guide treatments to reduce mortality and identify those likely to develop pulmonary hypertension.
How similar studies have performed: Several retrospective case series have described pulmonary artery involvement and pulmonary hypertension in Takayasu arteritis, but prospective, long-term analyses at a single center remain limited.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Hospitalized between Jan 1, 2016 and Dec 31, 2026 * Diagnosed with TAK according to the modified Ishikawa criteria and/or 1990 American College of Rheumatology criteria and/or 2022 ACR/EULAR criteria * Diagnosed with pulmonary artery involvement using computed tomography pulmonary angiography or transcatheter pulmonary angiography * Patients without aortic or primary branch involvement who nonetheless exhibited both clinical features and computed tomography-confirmed evidence of pulmonary artery involvement (PAI), after exclusion of other diseases causing pulmonary artery stenosis or occlusion Exclusion Criteria: * Patients with PAI caused by non-TAK diseases such as other types of vasculitis, fibrosing mediastinitis, pulmonary artery sarcoma, pulmonary sarcoidosis or chronic thromboembolic pulmonary hypertension
Where this trial is running
Beijing, Beijing Municipality
- China-Japan Friendship hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Study coordinator: Wanmu Xie, Doctor
- Email: xiewanmu@126.com
- Phone: 15611734410
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.